← Eichor
Study identifier: NCT02745158 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

Condition: Fibrodysplasia Ossificans Progressiva (FOP)  ·  Sponsor: The International FOP Association

PhaseN/A
Planned participants800
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Mark S Hamilton, PhD  ·  1-203-605-2122  ·  mark.hamilton@ifopa.org

Sammi Kile, MS  ·  1-720-341-6999  ·  registry@ifopa.org

Always discuss trial participation with your own doctor first.

Locations (1)

The International Fibrodysplasia Ossificans Progressiva Association (IFOPA)North Kansas City, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02745158